【中金:维持和黄医药(00013.HK)目标价30港元 评级“跑赢行业”】智通财经APP获悉,中金发布研报称,维持和黄医

智通财经
04 Jul
【中金:维持和黄医药(00013.HK)目标价30港元 评级“跑赢行业”】智通财经APP获悉,中金发布研报称,维持和黄医药(00013.HK)2025年/2026年归母净利润预测3.6亿美元/1.0亿美元不变。基于DCF模型,该行维持跑赢行业评级和目标价30港币不变,较当前股价有20.5%的上行空间。6月30日,公司公告赛沃替尼和奥希替尼联合疗法获得国家药监局批准,用于治疗EGFR突变且EGFR TKI治疗进展后伴MET扩增的局部晚期或转移性非鳞状非小细胞肺癌患者,此项批准亦将触发一项来自阿斯利康的1,100万美元的里程碑付款。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10